

**Table S7. Percentage of hyper Vif derivatives in intermediate A3H humanized mice infected with HIV-1 NLCSFV3.**

Mouse no.*	Donor lot*	<i>APOBE3H</i> haplotype		# Analyzed sequence	# Vif derivatives with anti-A3H activity	% Vif with anti-A3H-II activity†
50	Q	I / IV	Intermediate	42	0	0.0
51	Q	I / IV	Intermediate	49	0	0.0
52	L	I / I	Intermediate	27	0	0.0
<b>Average</b>				118	0	0.0
<b>SEM</b>						0.0

\* Identical to Figure S5A and Table S5.

† Percentage of hyper Vif derivatives and the hyper Vif derivatives acquiring anti-A3H-II activity.